ZURA Zura Bio Limited
USHealthcareAs of 2026-07-10 16:00
Why ZURA matters now
Zura Bio Limited (ZURA) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.11 with -7.26% on the session and $332.3M in market capitalization; recent performance reads 1-month -6.01% and YTD -28.44%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-24.2M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -29.8%.
The latest indexable market news headline is "Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00; recent insider activity includes Kulkarni Sandeep Chidambar filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.94
P/S
0.00
EV/EBITDA
-0.24
DCF Value
$1.15
FCF Yield
-29.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-54.6%
ROA
-33.0%
ROIC
-37.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-24.2M | $-0.22 |
| Q4 2025 | $0.00 | $-17.2M | $-0.49 |
| FY 2025 | $0.00 | $-68.7M | $-1.06 |
| Q3 2025 | $0.00 | $-18.0M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.03
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.